&w=3840&q=100)
Asston Pharmaceuticals IPO closes today; subscription rises 26x, GMP at 24%
The SME offering, which opened for public subscription on Wednesday, July 9, has received bids for 38.04 million shares, against 1.6 million shares on offer, leading to a subscription of 26.68 times, according to BSE data at 10:55 AM.
The demand was driven by retail investors and non-institutional investors (NIIs), who subscribed to their reserved portion by 33.10 times and 33.7 times, respectively. The qualified institutional buyers (QIBs) portion was subscribed 7.98 times.
Asston Pharmaceuticals IPO GMP
According to sources tracking unofficial markets, the unlisted shares of Asston Pharmaceuticals were trading at ₹153, commanding a premium of ₹30 or 24.39 per cent compared to the upper end of the price band of ₹115 to ₹123, on Friday, in the grey market.
Asston Pharmaceuticals IPO details
The company plans to raise ₹27.56 crore through a fresh issue of 2.24 million equity shares. There is no offer for sale (OFS) component. The SME IPO will close for subscription today, July 11, 2025. The basis of the allotment of shares is expected to be finalised on Monday, July 14, 2025. Shares of Asston Pharmaceuticals are scheduled to be listed on the BSE SME platform, tentatively on Wednesday, July 16, 2025.
Retail investors can bid for a minimum of two lots consisting of 1,000 shares each, with an investment amount of ₹2,46,000 at the upper price band. The minimum investment required for high-net-worth individuals (HNIs) is ₹3,69,000 for three lots of 3,000 equity shares.
Asston Pharmaceuticals IPO registrar
Maashitla Securities is the registrar of the issue. Sobhagya Capital Options is the sole book-running lead manager for the issue.
Asston Pharmaceuticals IPO objective
According to the red herring prospectus (RHP), the company plans to utilise the net issue proceeds for acquiring machinery in the manufacturing unit, meet working capital requirements and repay debt. The remaining funds will be used for general corporate purposes.
About Asston Pharmaceuticals
Incorporated in 2019, Asston Pharmaceuticals manufactures and exports both pharmaceutical formulations and nutraceutical products in domestic and various African and Asian markets. Currently, the company is involved in the business of manufacturing and marketing tablets, capsules, oral liquids, external preparations (Ointment, Cream, Gel, and Lotion), and oral powder (Sachet, Dry Syrup), etc. The company also manufactures various pharmaceutical products for different marketers on loan license or contract manufacturing basis.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
34 minutes ago
- Economic Times
Ashok Leyland 1:1 bonus issue record date tomorrow. Do you own?
Shares of Ashok Leyland will be in focus today, July 15, as it is the last day for investors to buy the stock to be eligible for the company's upcoming 1:1 bonus issue. The commercial vehicle major has fixed July 16, 2025, as the record date for determining eligible shareholders who will receive the bonus shares. ADVERTISEMENT In its exchange filing, Ashok Leyland announced that the deemed allotment date for the bonus shares is July 17, 2025, with trading in these shares expected to commence from Friday, July 18, 2025. The allotment committee confirmed that the record date of Wednesday, July 16, will serve to identify shareholders entitled to the bonus allotment. Following the allotment, the bonus shares will be credited and made available for trading on the next working day. The company had earlier announced the 1:1 bonus issue in May 2025, along with its March quarter results and dividend declaration. This marks Ashok Leyland's first bonus issue since 2011, when it had last offered a 1:1 Leyland shares, on Monday, closed 2.7% higher at Rs 252.90 on the BSE. ADVERTISEMENT In a recent note, domestic brokerage firm Angel One gave a target price of Rs 295 on the stock, along with a 'buy' rating, stating that the company may be a beneficiary of visible growth in the commercial vehicle Leyland plans Rs 1,000 crore capex in FY26, focusing on EVs, alternative fuels, and defence, which is expected to double in 2–3 years. ADVERTISEMENT Ashok Leyland holds over 30% market share in M&HCV and recently secured large orders, including 200 trucks from Instant Transport Solution and 250 trucks from Patanjali. Switch Mobility posted EBITDA-positive results with 1,800 EVs in the pipeline. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Economic Times
34 minutes ago
- Economic Times
HDB Financial Services to announce Q1 results today
Shares of HDB Financial Services will be in focus on Tuesday as the HDFC Bank's NBFC subsidiary will announce its Q1 earnings along with nearly two dozen BSE listed companies. It will be the company's first quarterly results since its listing on July 2. ADVERTISEMENT HDB Financial Services shares made a decent debut on the D-Street as the stock was listed at Rs 835, which was a 13% premium over the IPO price of Rs 740. On Monday, its shares closed at Rs 842.10, declining by Rs 3.55 or 0.42% over the Friday closing price. 891.90 The Rs 12,500 crore IPO—which comprised a fresh issue of Rs 2,500 crore and an offer-for-sale (OFS) of Rs 10,000 crore—was subscribed nearly 17.65 times. The issue garnered bids worth over Rs 1.61 lakh crore, underscoring strong investor interest despite broader market demand was primarily driven by institutional investors, with Qualified Institutional Buyers (QIBs) subscribing 55.47 times their allocated quota. In contrast, retail participation was modest, at just 1.4 times. Analysts say this divergence highlights differing investment motivations. Emkay Global was the first brokerage to initiate coverage on the newly listed stock, assigning a 'Buy' rating with a target price of Rs 900—implying a further upside of over 6%. The brokerage valued the stock at 3x FY27 price-to-book and expects robust performance through FY28. ADVERTISEMENT Emkay highlighted HDB Financial Services' scale and diversification, citing its granular and widespread lending franchise serving over 19 million customers across India. It noted the company's bottom-up growth strategy, extensive presence in remote locations—with more than 70% of branches in Tier 4 towns and beyond—and its focus on direct sourcing and underbanked customer segments. The Street will also keep its eyes on other notable results like HDFC Life Insurance Company, Reliance Industries promoted Hathway Cable & Datacom, ICICI Lombard General Insurance Company, Bank of Maharashtra, Network18 and Angel One. ADVERTISEMENT Also Read: HCL Tech Q1 Results: Cons PAT slips 10% YoY to Rs 3,843 crore; Rs 12 per share dividend declared (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Economic Times
34 minutes ago
- Economic Times
Glen Industries shares to list today. Check GMP ahead of debut
What the company does Live Events Financial performance (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Glen Industries are set to debut on the BSE SME platform on Tuesday following a strong response to its Rs 63.02 crore IPO. The public issue, entirely a fresh offer of 64.97 lakh shares, was subscribed a massive 260.28 times, making it one of the most oversubscribed SME IPOs of the IPO was priced at Rs 97 per share, and the company raised Rs 17.46 crore from anchor investors ahead of the offer. The strong demand came primarily from non-institutional investors (NIIs), whose quota was booked 476.25 times, followed by 225.15 times in the retail category and 192.46 times from qualified institutional buyers (QIBs).In the grey market, the IPO is currently commanding a GMP of Rs 49, suggesting a likely listing premium of around 51% over the issue in 2007, GLEN Industries manufactures eco-friendly food packaging and service products. Its main products include thin-wall food containers and compostable straws, catering to the food and beverage industry both domestically and globally. It exports to markets such as Europe, the US, Australia, the Middle East, and company recently expanded operations with a new 90,000 sq ft facility in West Bengal to meet growing posted a 113% YoY jump in net profit to Rs 18.27 crore for FY25, while EBITDA rose to Rs 40.43 crore, up from Rs 24.87 crore in the previous year. Its EBITDA margin stands at 23.6%, and the return on net worth (RoNW) is 45.43%, reflecting strong operating leverage.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
